Contact Congress about S. 1631: Restoring Safeguards for Dangerous Abortion Drugs Act

Patients could face tighter rules for getting mifepristone, including by mail. The bill would restore older FDA safety rules, ban imports, and allow some lawsuits over unlawfully shipped drugs.

Modern Action explains legislation in plain English, helps you choose whether to support, oppose, or ask for changes, and drafts a message tied to the bill, your stance, and the elected officials who can act on it.

Restoring Safeguards for Dangerous Abortion Drugs Act is a Senate bill in committee. The latest recorded action: Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

Latest action on S. 1631: Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

Who this affects: This bill mainly affects patients seeking mifepristone, health care providers who prescribe it, pharmacies that supply it, and companies or people who ship it. Patients could face fewer ways to get the drug, especially by mail or through telehealth. Providers, pharmacies, and shippers could face new lawsuits if they knowingly move the drug unlawfully. Drug makers and distributors outside the United States would also be affected by the import ban.

Why this matters: This bill matters because it could change where and how patients get mifepristone. Today, federal drug rules can change through the Food and Drug Administration process. This bill would freeze one older set of rules into law. It could also raise legal risk for telehealth providers, pharmacies, and shippers. The size of the impact would depend on enforcement, court decisions, and how the bill works alongside state laws.

Key provisions in S. 1631

• The Health and Human Services Secretary must cancel the current FDA safety rules for mifepristone within 90 days. The Secretary must bring back the rules from June 2011.
• Mifepristone must always have special FDA safety rules, called a Risk Evaluation and Mitigation Strategy. The Secretary cannot approve a version that differs from the June 2011 rules.
• Telehealth providers, pharmacies, and others can count as covered entities under the bill. This applies if they knowingly import or move mifepristone across state or national borders in violation of 18 U.S.C. 1462, an existing federal criminal law.
• People harmed after using that mifepristone could sue in federal or state court. The harm must involve bodily injury or mental health harm connected to the drug use.
• People who sue could ask for payment for their losses. They could also seek extra punishment damages, attorney's fees, and court costs.

How Modern Action helps you take action on S. 1631

You do not have to start with a blank letter. Modern Action turns the bill, your position, and the relevant congressional context into a message you can edit and send. The goal is to make contacting Congress clear, specific, and useful without forcing you to parse bill text or figure out the right office on your own.

Questions people ask about S. 1631

What is S. 1631?

Patients could face tighter rules for getting mifepristone, including by mail. The bill would restore older FDA safety rules, ban imports, and allow some lawsuits over unlawfully shipped drugs.

How do I support or oppose S. 1631?

Choose support, oppose, or ask for changes on Modern Action. The action flow drafts the message for you and keeps the wording tied to this bill.

Who should I contact about S. 1631?

Modern Action uses your location to route the action to the congressional offices relevant to the bill and your representation.

Can Modern Action explain S. 1631 before I act?

Yes. Modern Action gives you a plain-English summary, current status, and action context before you send anything.